A. Desai

发表

High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT.

S. de Denus, Jiankang Liu, B. Claggett, 2024, International journal of cardiology.

Strategies for multivessel revascularization in patients with diabetes.

G. Dangas, M. Farkouh, K. Ramanathan, 2012, The New England journal of medicine.

Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.

P. Jhund, M. Vaduganathan, S. Inzucchi, 2024, European journal of heart failure.

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.

Akshay S. Desai, S. Solomon, K. Dickstein, 2016, The New England journal of medicine.

Acute Heart Failure.

Scott D. Solomon, A. Desai, 2022, Advanced emergency nursing journal.

Heart failure, investigator-reported sleep apnea and dapagliflozin: A patient-level pooled meta-analysis of DAPA-HF and DELIVER.

P. Jhund, M. Vaduganathan, S. Inzucchi, 2023, Journal of cardiac failure.

Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial

P. Jhund, M. Vaduganathan, D. Lindholm, 2023, European journal of heart failure.

Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

P. Jhund, M. Vaduganathan, S. Inzucchi, 2023, JAMA cardiology.

Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER.

P. Jhund, M. Vaduganathan, F. Martinez, 2024, European journal of heart failure.

Feasibility of frailty screening among patients with advanced heart failure

MichaelJ Landzberg, H. Lehto, Akshay S. Desai, 2023, BMJ open quality.

Knowledge about self‐efficacy and outcomes in patients with heart failure and reduced ejection fraction

P. Jhund, M. Vaduganathan, M. Packer, 2023, European journal of heart failure.

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

James E. Tcheng, Christopher J. White, Norman L. Stockbridge, 2018, Circulation.

Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF

P. Jhund, M. Vaduganathan, Li Shen, 2024, European journal of heart failure.

Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials

P. Jhund, M. Vaduganathan, O. Vardeny, 2024, Journal of the American Heart Association.

Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF.

M. Vaduganathan, A. Shah, M. Gori, 2024, European journal of heart failure.

Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials.

P. Jhund, M. Vaduganathan, B. Claggett, 2024, JAMA cardiology.

Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

P. Jhund, M. Vaduganathan, F. Zannad, 2023, European journal of heart failure.

Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF

Akshay S. Desai, S. Solomon, M. Pfeffer, 2021, Journal of the American Heart Association.